Good Laboratory Practice (GLP)

ProPharma ensures global GLP and lab compliance with QMS development, inspection readiness, remediation, and quality oversight.

GLP Consulting Services

ProPharma's Quality & Compliance team offers Sponsors, laboratories, and CROs a full range of global good laboratory practice and compliance support services for Clinical Study, Pharmacy, CMO, CDMO, CROs, and third-party testing labs. We assist in achieving and maintaining full compliance with GLP, GCLP, OECD, CAP, and CLIA regulations. Our consultants combine deep regulatory knowledge, operational experience, and a global perspective to ensure your non-clinical, clinical development, and bio/analytical programs meet international standards to support compliance aspects such as:

smiling-woman-high-fiving-coworker-as-983431523-650x425

Illustration of ProPharma's Good Laboratory Practice (GLP) services overview

 

Gloved hand working with test tubes and vials in a lab

Nonclinical GLP Laboratory  Compliance Services

We offer comprehensive Good Laboratory Practice support for facilities, sponsors, and testing labs conducting regulated nonclinical safety and toxicology studies.

Our GLP services include:

  • GLP Facility & Study Conduct Audits
  • Bioanalytical and Histopathology Compliance Assessments
  • Test Article and Specimen Handling Reviews
  • Toxicology Study Design and In-Life Phase Oversight (In-Vivo / In-Vitro)
  • Data Integrity Audits (21 CFR Part 11, OECD, ALCOA+)
  • Regulatory Inspection Readiness (FDA, EMA, MHRA, PMDA)

Enabling IND/CTA/NDA Laboratory & Testing Compliance

We support the transition from discovery through Investigational New Drug (IND) and Clinical Trial Application (CTA) to New Drug Application (NDA) testing with compliance audits, quality management system support, data integrity monitoring, and QA oversight services.

Our services include:

  • GLP Oversight of IND/CTA-Supporting Studies
  • CRO and Laboratory Qualification Audits
  • Electronic Lab System Assessments (LIMS, ELN, CDS)
  • Sponsor Oversight SOPs and GLP Quality Systems
  • Regulatory Submission Readiness (IND, CTA)
Woman focused on injecting test tube

GCLP, CAP & CLIA Compliance for Clinical Trial Laboratory

Ensure your clinical trial testing laboratories meet GCLP, CLIA, and CAP requirements to support compliant and inspection-ready operations.

GCLP Compliance Services

For central labs, specialty labs, and sponsor-oversight programs: 

  • GCLP Audits and Mock Inspections
  • SOP Development for Sample Handling and Bioanalytical Testing
  • Chain of Custody and Logistics Reviews
  • Laboratory Vendor Qualification and Monitoring

CAP/CLIA Compliance Services (U.S. Labs)

For clinical labs performing testing under U.S. regulations: 

  • CLIA Certification Consulting and Gap Assessments
  • CAP Accreditation Preparation and Inspection Readiness
  • QMS Implementation and Lab Process Optimization
  • Response Planning for CAP/CLIA Deficiencies
  • Audit and Validation of Laboratory Information Systems (LIS)

Clinical and CMC Transition Support

We support clinical development teams as they interface with data from nonclinical and early CMC programs.

Services include:

  • GLP-to-GCP Data Traceability Audits
  • Oversight of Bioanalytical Labs Supporting Clinical Trials
  • Companion Diagnostic and Biomarker Lab Compliance Reviews
  • Technical Transfer
    and Method Transfer Compliance Reviews
  • GCLP/CMC Consulting for Clinical Sample Analysis

Analytical Testing Compliance for Sponsors

We help commercial and manufacturing organizations manage GLP-related functions within GxP environments.

Services include: 

  • Non-GMP Laboratory Phase Appropriate Best Scientific Practices Compliance
  • GLP Audit of R&D Labs within GMP Sites
  • Analytical Method Transfer Compliance Support
  • Stability and Shelf-Life Study Review

General Laboratory Compliance Services

Whether you're preparing for an inspection or establishing your first QA system, our global consultants can help.

  • Global Regulatory Intelligence (FDA, EMA, MHRA, OECD, WHO)
  • SOP Development & GLP/GCLP Policy Creation
  • Staff Training (GLP, GCLP, CAP, CLIA, Data Integrity)
  • CAPA Planning
    and Remediation Project Management
  • Mock Inspections and Enforcement Readiness Support
  • Quality System Development and Staff Augmentation

Partner with ProPharma for Good Laboratory Practice Services

Partner with us for expert laboratory compliance and quality solutions. Contact ProPharma today to learn how we can support your organization's laboratory Quality Assurance needs.

News & Insights

Modernizing Case Management for Global Compliance

June 8, 2026

Modernizing Case Management for Global Compliance

Discover how E2B (R3) is modernizing pharmacovigilance case management, improving compliance, and streamlining adverse event reporting across global regulatory authorities.

Accelerating European Market Entry: The Strategic Advantage of Using FDA Approval in the UK’s IRP

June 4, 2026

Accelerating European Market Entry: The Strategic Advantage of Using FDA Approva...

Learn how the UK's IRP can help FDA-approved therapies achieve faster UK market access, accelerate launch sequencing, and support global regulatory strategy.

Why Medical Information Is Critical to Adverse Event Reporting

June 1, 2026

Why Medical Information Is Critical to Adverse Event Reporting

Discover the vital role of Medical Information in adverse event reporting and how it enhances patient safety and regulatory compliance in the pharmaceutical industry.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Case Study Reestablishing FDA Alignment After a CMC Disruption: A Strategic Path to BLA Approval

May 20, 2026

From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...

A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...

Case Study Response to Regulatory Request with Subsequent Full Signal Assessment

May 15, 2026

Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...

Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

Modernizing Case Management for Global Compliance

June 8, 2026

Modernizing Case Management for Global Compliance

Discover how E2B (R3) is modernizing pharmacovigilance case management, improving compliance, and streamlining adverse event reporting across global regulatory authorities.

Accelerating European Market Entry: The Strategic Advantage of Using FDA Approval in the UK’s IRP

June 4, 2026

Accelerating European Market Entry: The Strategic Advantage of Using FDA Approva...

Learn how the UK's IRP can help FDA-approved therapies achieve faster UK market access, accelerate launch sequencing, and support global regulatory strategy.

Why Medical Information Is Critical to Adverse Event Reporting

June 1, 2026

Why Medical Information Is Critical to Adverse Event Reporting

Discover the vital role of Medical Information in adverse event reporting and how it enhances patient safety and regulatory compliance in the pharmaceutical industry.

Previous Post Arrow Next Post Arrow
ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Case Study Reestablishing FDA Alignment After a CMC Disruption: A Strategic Path to BLA Approval

May 20, 2026

From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...

A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...

Case Study Response to Regulatory Request with Subsequent Full Signal Assessment

May 15, 2026

Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...

Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow